Business Description
SELLAS Life Sciences Group Inc
NAICS : 325412
SIC : 2834
ISIN : US81642T1007
Description
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.51 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 13.8 | |||||
| 3-Year EPS without NRI Growth Rate | 14.4 | |||||
| 3-Year FCF Growth Rate | -0.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 31.73 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.84 | |||||
| 9-Day RSI | 39.88 | |||||
| 14-Day RSI | 43.52 | |||||
| 6-1 Month Momentum % | -12.14 | |||||
| 12-1 Month Momentum % | 23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.26 | |||||
| Quick Ratio | 2.26 | |||||
| Cash Ratio | 1.98 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -31.1 | |||||
| Shareholder Yield % | -58.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -967.28 | |||||
| ROA % | -200.84 | |||||
| ROIC % | -645.19 | |||||
| ROC (Joel Greenblatt) % | -4901.59 | |||||
| ROCE % | -920.67 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.68 | |||||
| Price-to-Tangible-Book | 5.32 | |||||
| EV-to-EBIT | -1.95 | |||||
| EV-to-EBITDA | -1.95 | |||||
| EV-to-Forward-Revenue | 2.2 | |||||
| EV-to-FCF | -1.94 | |||||
| Price-to-Net-Current-Asset-Value | 5.57 | |||||
| Price-to-Net-Cash | 7.31 | |||||
| Earnings Yield (Greenblatt) % | -51.28 | |||||
| FCF Yield % | -40.16 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SELLAS Life Sciences Group Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.69 | ||
| Beta | 2.85 | ||
| Volatility % | 80.21 | ||
| 14-Day RSI | 43.52 | ||
| 14-Day ATR ($) | 0.086626 | ||
| 20-Day SMA ($) | 1.224 | ||
| 12-1 Month Momentum % | 23 | ||
| 52-Week Range ($) | 0.4986 - 1.72 | ||
| Shares Outstanding (Mil) | 70.38 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SELLAS Life Sciences Group Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SELLAS Life Sciences Group Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
SELLAS Life Sciences Group Inc Frequently Asked Questions
What is SELLAS Life Sciences Group Inc(SLS)'s stock price today?
The current price of SLS is $1.17. The 52 week high of SLS is $1.72 and 52 week low is $0.50.
When is next earnings date of SELLAS Life Sciences Group Inc(SLS)?
The next earnings date of SELLAS Life Sciences Group Inc(SLS) is 2025-02-13 Est..
Does SELLAS Life Sciences Group Inc(SLS) pay dividends? If so, how much?
SELLAS Life Sciences Group Inc(SLS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers